Steven Peskin, MD, MBA, FACP: [What is the economic value of patient assistance programs?] [When] patient assistance programs are for individuals where there is economic hardship, and a biopharmaceutical company deems that it is appropriate, compassionate, and ethical to provide some assistance to select patients, then I think [they are] a very worthy thing.

There are other types of patient support programs. When most people mention patient assistance, they’re thinking of some economic or financial assistance. Sometimes, there might even be free medication given to certain people who can’t afford those medicines in the diabetes space or other areas. Again, those things are laudable, and worthy, and compassionate.

With adherence, endurance, persistency, or side effect management, sure, those things, we recognize, are ongoing. For some of those efforts, we will work and join with certain companies. In particular areas, we worked with one company around educating some of our folks that work in care coordination on end-of-life issues and palliative care. That’s been an area where we’ve worked through educational opportunities with biopharmaceutical companies. Those kinds of things, where the patient journey can be supported, or assisted, as it relates to a particular cancer episode, are appropriate, and we’ll certainly welcome that help from life sciences companies.

[When it comes to] educating our members, again, we have programs where we will occasionally work together. We’ve done this in diabetes. I don’t know that we’ve done this in cancer, specifically, but those are potentially available opportunities.

Again, we’ve worked with certain biopharmaceutical companies to educate some of our care coordinators or care managers as it relates to particular emerging science in a particular cancer type or, again, as I mentioned earlier, palliative care and advanced illness.

The Value of Patient Assistance Programs

Steven Peskin, MD, MBA, FACP, discusses how his organization has collaborated with certain companies to educate key stakeholders regarding important topics in cancer care, and the impact of these collaborations in terms of the establishment of patient assistance programs in oncology.
Published Online: November 02, 2016
View More From This Discussion
Episode 1 Existing Treatment Landscape of Immunotherapies
Episode 2 Clinical Insights on Newer Immunotherapies in Lung Cancer
Episode 3 Immunotherapy in Oncology and the Role of the PD-L1 Biomarker
Episode 4 Early Biomarkers and Coverage Decisions in Immuno-Oncology
Episode 5 How Important Are Biomarkers for Treatment Selection in Lung Cancer?
Episode 6 Predictive Biomarker Testing for Immunotherapy in Melanoma
Episode 7 Health Plan Coverage of Diagnostic Tests for PD-L1 Expression
Episode 8 Distinguishing Between Companion and Complementary Diagnostic Tests
Episode 9 Clinical Pathways Should Keep Pace With New Data
Episode 10 Health Plan Perspectives on Clinical Pathways
Episode 11 Clinician Concerns with Adopting Clinical Pathways
Episode 12 Safety and Efficacy of Targeted Therapy Versus Immunotherapy in Melanoma
Episode 13 Clinical Pathway Consideration and Payer Decisions
Episode 14 Understanding Immunotherapy Efficacy and Safety
Episode 15 Combination Immunotherapies in Melanoma
Episode 16 Payer Concerns With Including Novel Immunotherapies on Clinical Pathways
Episode 17 Combination Therapies: What Works Best for Immuno-Oncology?
Episode 18 Improving Patient Access-Rapid Approval and Patient Assistance Programs
Episode 19 Health Plan Take on the Cancer Drug Approval Process and Surrogate Endpoints
Episode 20 The Unmet Need in Immuno-Oncology and New Drug Approvals
Episode 21 Value Benchmarks in Immuno-Oncology
Episode 22 Do Oncologists Contemplate Patient Cost Sharing?
Episode 23 Importance of Patient Assistance Programs in Oncology
Episode 24 Payer Stance on Immunotherapy in Oncology Care
Episode 25 Influence of Biomarkers in Immunotherapy Treatment Decisions
Episode 26 Appropriate Use of Companion Versus Complementary Diagnostics
Episode 27 Clinical Pathways
Episode 28 Do Accelerated Review and Narrow Indications Influence Payer Decisions?
Episode 29 The Value of Patient Assistance Programs
$RAmodule$